Form 4: Emergent BioSolutions Director Kathryn C. Zoon Reports Stock Sale
SEC Form 4 Filing
Director Kathryn C. Zoon reports selling 1,089 shares of Emergent BioSolutions Inc. (EBS) at $5.78 per share on May 21, 2024, pursuant to a pre-arranged trading plan.
Summary
- Kathryn C. Zoon, a director of Emergent BioSolutions Inc., reported a transaction involving the company's common stock.
- On May 21, 2024, Ms. Zoon sold 1,089 shares of common stock at a price of $5.78 per share.
- The sale was executed under a pre-existing trading plan adopted on June 15, 2022.
- Following the transaction, Ms. Zoon beneficially owns 48,882 shares of Emergent BioSolutions Inc.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's future.
Industry Context
This is a routine disclosure of a transaction by a company insider. It's important to monitor insider transactions as they can provide insights into management's perspective on the company's valuation and future prospects. However, sales under pre-arranged trading plans are less indicative of immediate sentiment.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the small volume of shares sold.
Key Dates
| Date | Description |
|---|---|
| June 15, 2022 | Date of adoption of the trading plan by Ms. Zoon |
| May 21, 2024 | Date of the stock sale transaction |
| May 23, 2024 | Date of signature of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.